Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

251 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review.
Crijns HJ, Straus SM, Gispen-de Wied C, de Jong-van den Berg LT. Crijns HJ, et al. Br J Dermatol. 2011 Feb;164(2):238-44. doi: 10.1111/j.1365-2133.2010.09976.x. Br J Dermatol. 2011. PMID: 20716214 Review.
Drug safety in pregnancy--monitoring congenital anomalies.
Morgan M, De Jong-van den Berg LT, Jordan S. Morgan M, et al. J Nurs Manag. 2011 Apr;19(3):305-10. doi: 10.1111/j.1365-2834.2011.01250.x. J Nurs Manag. 2011. PMID: 21507101
Healthcare professional surveys to investigate the implementation of the isotretinoin Pregnancy Prevention Programme: a descriptive study.
Crijns I, Mantel-Teeuwisse A, Bloemberg R, Pinas E, Straus S, de Jong-van den Berg L. Crijns I, et al. Expert Opin Drug Saf. 2013 Jan;12(1):29-38. doi: 10.1517/14740338.2013.745850. Epub 2012 Nov 20. Expert Opin Drug Saf. 2013. PMID: 23163396
Implementation of the harmonized EU isotretinoin Pregnancy Prevention Programme: a questionnaire survey among European regulatory agencies.
Crijns I, Straus S, Luteijn M, Gispen-de Wied C, Raine J, de Jong-van den Berg L. Crijns I, et al. Drug Saf. 2012 Jan 1;35(1):27-32. doi: 10.2165/11595570-000000000-00000. Drug Saf. 2012. PMID: 22050373
A comparison of pregnancy prevention programmes in Europe.
Crijns I, Zomerdijk I, Sturkenboom M, de Jong-van den Berg L, Straus S. Crijns I, et al. Expert Opin Drug Saf. 2014 Apr;13(4):411-20. doi: 10.1517/14740338.2014.887678. Epub 2014 Feb 8. Expert Opin Drug Saf. 2014. PMID: 24506812
EUROmediCAT signal detection: a systematic method for identifying potential teratogenic medication.
Luteijn JM, Morris JK, Garne E, Given J, de Jong-van den Berg L, Addor MC, Bakker M, Barisic I, Gatt M, Klungsoyr K, Latos-Bielenska A, Lelong N, Nelen V, Neville A, O'Mahony M, Pierini A, Tucker D, de Walle H, Wiesel A, Loane M, Dolk H. Luteijn JM, et al. Br J Clin Pharmacol. 2016 Oct;82(4):1110-22. doi: 10.1111/bcp.13056. Epub 2016 Aug 4. Br J Clin Pharmacol. 2016. PMID: 27353147 Free PMC article.
Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study.
Jentink J, Dolk H, Loane MA, Morris JK, Wellesley D, Garne E, de Jong-van den Berg L; EUROCAT Antiepileptic Study Working Group. Jentink J, et al. BMJ. 2010 Dec 2;341:c6581. doi: 10.1136/bmj.c6581. BMJ. 2010. PMID: 21127116 Free PMC article. Review.
The limitations of some European healthcare databases for monitoring the effectiveness of pregnancy prevention programmes as risk minimisation measures.
Charlton RA, Bettoli V, Bos HJ, Engeland A, Garne E, Gini R, Hansen AV, de Jong-van den Berg LTW, Jordan S, Klungs√łyr K, Neville AJ, Pierini A, Puccini A, Sinclair M, Thayer D, Dolk H. Charlton RA, et al. Among authors: de jong van den berg ltw. Eur J Clin Pharmacol. 2018 Apr;74(4):513-520. doi: 10.1007/s00228-017-2398-9. Epub 2017 Dec 11. Eur J Clin Pharmacol. 2018. PMID: 29230493
Insulin analogues in pregnancy and specific congenital anomalies: a literature review.
de Jong J, Garne E, Wender-Ozegowska E, Morgan M, de Jong-van den Berg LT, Wang H. de Jong J, et al. Among authors: de jong van den berg lt. Diabetes Metab Res Rev. 2016 May;32(4):366-75. doi: 10.1002/dmrr.2730. Epub 2015 Nov 6. Diabetes Metab Res Rev. 2016. PMID: 26431249 Review.
Drugs associated with teratogenic mechanisms. Part II: a literature review of the evidence on human risks.
van Gelder MM, de Jong-van den Berg LT, Roeleveld N. van Gelder MM, et al. Hum Reprod. 2014 Jan;29(1):168-83. doi: 10.1093/humrep/det370. Epub 2013 Oct 9. Hum Reprod. 2014. PMID: 24108217 Review.
251 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page